Ryoncil® fda approval and market launch highlighted at tandem transplantation meetings

New york, feb. 13, 2025 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently approved product ryoncil® (remestemcel-l) is being highlighted at the 2025 transplantation & cellular therapy tandem meetings of the american society for transplantation and cellular therapy (astct) and the center for blood and marrow transplant research (cibmtr), the industry's premier conference taking place this week in honolulu, hi.
MESO Ratings Summary
MESO Quant Ranking